ArticleCureus2025
Preoperative Temporal Muscle Volume as an Independent Prognostic Marker in Glioblastoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveSarcopenia has emerged as a relevant prognostic factor across solid tumors, but its impact in glioblastoma is not fully defined. Temporal muscle measurements on routine cranial imaging offer a pragmatic surrogate of systemic muscle mass in patients who rarely undergo body computed tomography (CT). This study aimed to evaluate whether preoperative bilateral temporal muscle volume is associated with overall survival in adults with glioblastoma, independently of established clinical and molecular prognostic factors.
methodsWe conducted a retrospective, single-center cohort study including 83 adults with histologically confirmed glioblastoma who underwent tumor-directed neurosurgical procedures between January 2020 and July 2024 and had preoperative imaging suitable for temporal muscle assessment. Bilateral temporal muscle volume was obtained by summing right and left temporal muscle volumes and analyzed as a continuous variable and as a dichotomous variable based on the cohort median. Overall survival, defined from last tumor-directed surgery to death or last follow-up, was analyzed using Kaplan-Meier methods and Cox proportional hazards regression adjusted for age, sex, preoperative Karnofsky Performance Status, surgery type, postoperative treatment, isocitrate dehydrogenase mutation status, and O6-methylguanine-DNA methyltransferase promoter methylation status.
resultsPatients in the low-volume group had shorter median overall survival than those in the high-volume group (312 vs 492 days, log-rank p = 0.003). Temporal muscle volume correlated positively with survival time (Spearman r = 0.37, p = 0.001), whereas age correlated negatively (r = -0.35, p = 0.002). In multivariable analysis, higher temporal muscle volume remained independently associated with reduced mortality risk (hazard ratio per standard-deviation increase 0.68, 95% confidence interval 0.52-0.89, p = 0.004).
conclusionPreoperative bilateral temporal muscle volume is an independent prognostic marker in glioblastoma and may help refine risk stratification and guide supportive care in routine neuro-oncologic practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.